• 主页
  • 查找结果
  • The therapeutic efficacy of propranolol in children with recurrent primary epistaxis.

The therapeutic efficacy of propranolol in children with recurrent primary epistaxis.

Drug design, development and therapy (2013-03-08)
Bojko Bjelakovic, Mila Bojanovic, Stevo Lukic, Ljiljana Saranac, Vladislav Vukomanovic, Sergej Prijic, Nikola Zivkovic, Dusica Randjelovic
摘要

We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5-2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis.

材料
货号
品牌
产品描述

Sigma-Aldrich
(±)-普萘洛尔 盐酸盐, ≥99% (TLC), powder
Supelco
盐酸普萘洛尔, Pharmaceutical Secondary Standard; Certified Reference Material
普萘洛尔 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Supelco
Propranolol hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®